&nbsp;

January-2025-Colposcopy-CoP.pdf

Feb 2025

Regimen

CHOP+R

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

CISPFU+ZOLB; FU+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

CRBPFU+ZOLB; FU+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

CAPECISP+ZOLB; CAPE+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

CAPECRBP+ZOLB; CAPE+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Document

CART-cellTherapyforAdult RelapsedrefractoryLymphomaThirdorSubsequentLine.pdf

Apr 2025

Document

CART-cellTherapyforAdultRelapsedrefractoryLymphomaThirdorSubsequentLine.pdf

Apr 2025

Document

ClearCellOvarianCancerTreatmentPathwayMap.pdf

Apr 2025

Regimen

CRBPPACL+PEMB

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

CISPPEME+PEMB

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal),

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

CRBPPEME+PEMB

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal),

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Drugs Used: